Stock Scorecard
Stock Summary for Jaguar Health Inc (JAGX) - $0.49 as of 3/10/2026 1:55:36 AM EST
Total Score
9 out of 30
Safety Score
30 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for JAGX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for JAGX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for JAGX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for JAGX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for JAGX (30 out of 100)
| Stock Price Rating (Max of 10) | 1 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for JAGX
Financial Details for JAGX
Company Overview |
|
|---|---|
| Ticker | JAGX |
| Company Name | Jaguar Health Inc |
| Country | USA |
| Description | Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/30/2026 |
Stock Price History |
|
| Last Day Price | 0.49 |
| Price 4 Years Ago | 9,776.25 |
| Last Day Price Updated | 3/10/2026 1:55:36 AM EST |
| Last Day Volume | 1,278,517 |
| Average Daily Volume | 534,886 |
| 52-Week High | 15.48 |
| 52-Week Low | 0.47 |
| Last Price to 52 Week Low | 4.26% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.38 |
| Sector PE | 94.10 |
| 5-Year Average PE | -303.72 |
| Free Cash Flow Ratio | 0.58 |
| Industry Free Cash Flow Ratio | 12.54 |
| Sector Free Cash Flow Ratio | 23.93 |
| Current Ratio Most Recent Quarter | 0.81 |
| Total Cash Per Share | 0.84 |
| Book Value Per Share Most Recent Quarter | 0.85 |
| Price to Book Ratio | 1.68 |
| Industry Price to Book Ratio | 8.37 |
| Sector Price to Book Ratio | 9.87 |
| Price to Sales Ratio Twelve Trailing Months | 0.45 |
| Industry Price to Sales Ratio Twelve Trailing Months | 29.33 |
| Sector Price to Sales Ratio Twelve Trailing Months | 10.68 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 11,218,700 |
| Market Capitalization | 5,497,163 |
| Institutional Ownership | 1.44% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 6.80% |
| Reported EPS 12 Trailing Months | -2.58 |
| Reported EPS Past Year | -35.31 |
| Reported EPS Prior Year | -130.96 |
| Net Income Twelve Trailing Months | -40,293,000 |
| Net Income Past Year | -38,492,000 |
| Net Income Prior Year | -41,300,000 |
| Quarterly Revenue Growth YOY | -0.80% |
| 5-Year Revenue Growth | 15.14% |
| Operating Margin Twelve Trailing Months | -234.80% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 3,527,000 |
| Total Cash Past Year | 8,002,000 |
| Total Cash Prior Year | 6,469,000 |
| Net Cash Position Most Recent Quarter | -4,121,000 |
| Net Cash Position Past Year | -15,501,000 |
| Long Term Debt Past Year | 23,503,000 |
| Long Term Debt Prior Year | 30,993,000 |
| Total Debt Most Recent Quarter | 7,648,000 |
| Equity to Debt Ratio Past Year | 0.24 |
| Equity to Debt Ratio Most Recent Quarter | 0.42 |
| Total Stockholder Equity Past Year | 7,285,000 |
| Total Stockholder Equity Prior Year | 4,961,000 |
| Total Stockholder Equity Most Recent Quarter | 5,627,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -26,508,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.36 |
| Free Cash Flow Past Year | -29,615,000 |
| Free Cash Flow Prior Year | -33,242,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.02 |
| MACD Signal | -0.01 |
| 20-Day Bollinger Lower Band | 0.91 |
| 20-Day Bollinger Middle Band | 0.91 |
| 20-Day Bollinger Upper Band | 0.91 |
| Beta | 0.05 |
| RSI | 38.80 |
| 50-Day SMA | 163.87 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 3/12/2026 1:41:22 AM EST |